Navigation Links
Mike Burgess Named Head of Oncology Discovery Translational Area for Roche's Pharma Research and Early Development (pRED) Organization
Date:4/22/2010

NUTLEY, N.J., April 22 /PRNewswire/ -- Roche announced today that Mike Burgess, M.D., Ph.D., has been named Head of the Oncology Discovery and Translational Area (DTA) (1), effective immediately.  The Oncology DTA is one of five disease-focused organizations at Roche, and as part of the Pharma Research and Early Development (pRED) organization, oversees research and early development up to late stage development in the field of Oncology.

Most recently, Mike was Head of Academic Alliances (part of pRED Development), based in Welwyn, UK.  He will be relocating to Nutley, NJ, as he assumes his new responsibilities.  Mike joined Roche in early 2006 as Clinical Research and Licensing Liaison, Oncology, for Roche Products Ltd., coming from Eli Lilly and Company where he was a Medical Fellow from April 1999 to January 2006.  In May 2008, he became the European Head of Roche's Clinical Research Early Development unit in its Oncology franchise.

Mike is a physician scientist with a Ph.D. in molecular biology and specialist clinical experience in pediatrics and pediatric oncology.  He received his medical training and his Ph.D. at the University of Bristol.  He is a member of London's Royal College of Physicians and the Royal College of Pediatrics and Child Health.

During his career, Mike has led the global development of a wide variety of anticancer agents (antibodies, nucleic acids, chemotherapy, targeted small molecules).

Roche currently has 17 new molecular entities (NMEs) for the disease in phase I and II.  Five cancer medicines -- Avastin, Herceptin, MabThera/Rituxan, Tarceva  and Xeloda -- accounted for about half of Roche's total pharmaceutical sales in 2009.  (link to Roche's current Oncology pipeline)

"Mike's appointment reinforces Roche's continuing commitment to maintain its standing as the world leader in innovative cancer therapies," said Jean-Jacques Garaud, Global Head of pRED.  "His strong vision of the importance of translational medicine in drug discovery and development and deep understanding of the development process will serve Roche well as we address the challenge of bringing differentiated medicines to oncology patients with unmet medical needs."

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D ($9.1B US). The Group posted sales of 49.1 billion Swiss francs ($45.1B US). Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-nutley.com.

1) There are five Discovery and Translation Areas within Roche's Pharma Research and Early Development organization that oversee research and early development up to full development decisions.  The other DTAs are focused on Central Nervous System, Inflammation, Metabolics and Virology.


'/>"/>
SOURCE Roche
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aspirin Named 8th World Wonder by Majority of Americans
2. American Board of Internal Medicine President Named to Alzheimers Study Group
3. New York Infection Prevention Expert Named Recipient of Carole DeMille Award
4. Pharmaxis Establishes Named Patient Program for Bronchitol
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes
7. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
8. Ikaria(R) Named Private Company of the Year by New Jersey Technology Council
9. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
10. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
11. EMD Serono, Inc. Named as a Top Employer by Science Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... SCOTTSDALE, Ariz. , Jan. 17, 2017 ... retired US Navy Capt. Mark Kelly as ... (ACMA) 2017 National Conference in Washington D.C. ... shuttle commander, will speak on Friday morning, April 21 ... management professionals from across the country are expected to ...
(Date:1/17/2017)...  OrthoAccel ® Technologies, Inc. announces that the ... "The Effect of Vibration on Molar Distalization," a study ... S. Jay Bowman , this prospective, peer-reviewed clinical study ... Technology ® speeds up molar distalization rates in ... of days to move the upper molars into a ...
(Date:1/17/2017)... DIEGO , Jan. 17, 2017   Tocagen Inc ., ... Jolly , Ph.D., executive vice president, research and pharmaceutical development at ... 2017 , to be held Jan. 17-20 in Miami ... as follows: ... A biotech oxymoron: exciting manufacturing for replicating viruses - what to ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... 17, 2017 , ... Today, to help those who are ... uplifting interview with medical expert and prolific author, Dr. Bernie Siegel. ... times, Dr. Bernie Siegel energizes listeners to live life with intrigue, magic and ...
(Date:1/17/2017)... Chapel, Florida (PRWEB) , ... January 17, 2017 ... ... Connected City, a new 21st century approach to infusing high speed technology into ... an area exclusively dedicated to the advancement of healthcare and wellness in a ...
(Date:1/17/2017)... New York (PRWEB) , ... January 17, 2017 ... ... network – SightMD – will lecture to primary eye care practitioners on the ... conditions at the upcoming 13th Semi-Annual Continuing Education Symposium, according to eye surgeon, ...
(Date:1/17/2017)... ... 17, 2017 , ... SC&H Group, a leading audit, tax, and consulting firm, ... IT Advisory Services practice . Rossi is the third technology consulting leader to join ... guidance grows, and the practice continues to expand.     , Bringing more than 25 years ...
(Date:1/17/2017)... York, NY (PRWEB) , ... January 17, 2017 ... ... Inc. Magazine’s fastest-growing private companies and ranked among the top US security companies ... Board of Directors. This announcement brings a year-long independent board nomination process ...
Breaking Medicine News(10 mins):